Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3228836 + nucleos(t)ide therapy
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Oral
01
Overview
**GSK3228836 + nucleos(t)ide therapy** is a combination regimen used in the treatment of chronic hepatitis B virus (HBV) infection[2][4]. GSK3228836 (bepirovirsen) is an antisense oligonucleotide that targets and degrades hepatitis B viral RNA, thereby reducing production of viral proteins (including HBsAg) and viral replication[2][3]. Nucleos(t)ide analogs (NAs) are small molecule antivirals (e.g., tenofovir, entecavir), which inhibit HBV reverse transcriptase, suppressing viral DNA synthesis. This combination is under investigation for its potential to achieve functional cure in chronic HBV by sequentially or concurrently suppressing viral replication and antigen expression[2][4].
- Other names
- bepirovirsen + nucleos(t)ide analog
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on GSK3228836 + nucleos(t)ide therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3228836 + nucleos(t)ide therapy.